Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials

BACKGROUND AND AIMS: In the 4-week GAIN clinical trial, adalimumab was efficacious in inducing remission in patients with moderate-to-severe Crohn’s disease [CD] who had prior loss of response/intolerance to infliximab. The efficacy and safety of adalimumab in these patients are reported here for up...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Crohns Colitis
Κύριοι συγγραφείς: Panaccione, Remo, Sandborn, William J, D’Haens, Geert, Wolf, Douglas C, Berg, Sofie, Maa, Jen-fue, Petersson, Joel, Robinson, Anne M
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Oxford University Press 2018
Θέματα:
Original Articles
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6065484/
https://ncbi.nlm.nih.gov/pubmed/29697818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjy050
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια